As Iconovo solidifies its product development and takes aim at a global market, a new analysis by Danske Bank indicates that the inhaler development company represents a significant market opportunity, thanks to its scalable business model in particular. The analysis values the company at 78-101 SEK per share – at least a 32 per cent increase from the current share price.

Read more